MedTrace Logo

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

NCT07489651 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-05-18

No results posted yet for this study

Summary

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.

Conditions

Interventions

DRUG

RE104 for Injection

Single, subcutaneous dose of RE104 for Injection

DRUG

Placebo

Single, subcutaneous dose of 0.9% sodium chloride for injection

Sponsors & Collaborators

  • Reunion Neuroscience Inc

    lead INDUSTRY

Principal Investigators

  • Mark Pollack, M.D. · Reunion Neuroscience Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-20
Primary Completion
2027-02-28
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07489651 on ClinicalTrials.gov